Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO Study
Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO Study
复制标题
DOI：
10.1136/hrt.2010.195057
复制
发表时间：
2010-08-01
期刊：
影响因子：
5.7
通讯作者：
Limbruno, Ugo
中科院分区：
文献类型：
--
作者：
Cortese, Bernardo;Micheli, Andrea;Limbruno, Ugo
小血管的经皮冠状动脉介入治疗（PCI）受到再狭窄和不良结局风险增加的限制，即使使用药物洗脱支架（DES）。近年来，紫杉醇涂层球囊（PCB）已被证明可减少支架内再狭窄情况下的新生内膜增生和靶病变血运重建（TLR）的需要。在PICCOLETO随机临床试验中，对接受小冠状血管PCI的稳定型或不稳定型心绞痛患者（
Background Percutaneous coronary intervention (PCI) of small vessels is limited by an increased risk of restenosis and adverse outcome, even when drug-eluting stents (DES) are employed. In recent years, the paclitaxel-coated balloon (PCB) has been shown to reduce neointimal proliferation and the need for target lesion revascularization (TLR) in an in-stent restenosis setting. The impact of a PCB during PCI of small coronary vessels was evaluated and compared to one of the most widely used DES.Methods In the PICCOLETO randomised clinical trial, patients with stable or unstable angina undergoing PCI of small coronary vessels (